Observational studyLung2015
Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
Observational study in Lung, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Trial
- Article
- An integrated proteomic classifier to distinguish benign from malignant pulmonary nodules.Clinical proteomics · 2025Article
- Biomarkers in lung cancer diagnosis and bronchoscopy: Current landscape and future directions.Cancer biomarkers : section A of Disease markers · 2025Review
- Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules.Journal of thoracic disease · 2023Article
- Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study.PloS one · 2023Observational
- Comparing modalities for risk assessment in patients with pulmonary lesions and nondiagnostic bronchoscopy for suspected lung cancer.BMC pulmonary medicine · 2022Article
- Design and Characterization of a Novel Blood Collection and Transportation Device for Proteomic Applications.Diagnostics (Basel, Switzerland) · 2020Article
- Biomarkers for Lung Cancer Screening and Detection.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Article
- Noninvasive biomarkers for lung cancer diagnosis, where do we stand?Journal of thoracic disease · 2020Review
- Observational
- Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles.Cancer immunology, immunotherapy : CII · 2018Article
- The building blocks of successful translation of proteomics to the clinic.Current opinion in biotechnology · 2018Review
- Evaluation of a Serum Lung Cancer Biomarker Panel.Biomarker insights · 2018Article
- An integrated risk predictor for pulmonary nodules.PloS one · 2017Article
- The Pursuit of Noninvasive Diagnosis of Lung Cancer.Seminars in respiratory and critical care medicine · 2016Review
- Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection.American journal of respiratory and critical care medicine · 2016Article
- Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Evaluation of indeterminate pulmonary nodules is a complex challenge. Most are benign but frequently undergo invasive and costly procedures to rule out malignancy. A plasma protein classifier was developed that identifies likely benign nodules that can be triaged to CT surveillance to avoid unnecessary invasive procedures. The clinical utility of this classifier was assessed in a prospective-retrospective analysis of a study enrolling 475 patients with nodules 8-30 mm in diameter who had an invasive procedure to confirm diagnosis at 12 sites. Using this classifier, 32.0 % (CI 19.5-46.7) of surgeries and 31.8 % (CI 20.9-44.4) of invasive procedures (biopsy and/or surgery) on benign nodules could have been avoided. Patients with malignancy triaged to CT surveillance by the classifier would have been 24.0 % (CI 19.2-29.4). This rate is similar to that described in clinical practices (24.5 % CI 16.2-34.4). This study demonstrates the clinical utility of a non-invasive blood test for pulmonary nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.